Peregrine Finalizes Phase III Trial Design

Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) reached an agreement with the Food and Drug Administration on the design of a Phase III trial for its lung cancer treatment bavituximab. Shares of the biopharmaceutical rose 28 cents to $1.82.


Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here